Patents Assigned to The Corporation of the Trustees of the Order of the Sisters
of Mercy in Queensland
-
Patent number: 8895698Abstract: The present invention relates to the field of diagnostics, therapeutics and immunological reagents. More particularly, the present invention provides binding partners of antibodies specific for dendritic cell (DC) antigens. The present invention further provides diagnostic and/or therapeutic agent based on the binding partners or antibodies specific for the binding partners.Type: GrantFiled: September 7, 2012Date of Patent: November 25, 2014Assignee: The Corporation of the Trustees of the Order of the Sisters of Mercy in QueenslandInventors: Derek Nigel Hart, David Munster, Peter Vukovic
-
Publication number: 20130085261Abstract: The present invention relates to the field of diagnostics, therapeutics and immunological reagents. More particularly, the present invention provides binding partners of antibodies specific for dendritic cell (DC) antigens. The present invention further provides diagnostic and/or therapeutic agent based on the binding partners or antibodies specific for the binding partners.Type: ApplicationFiled: September 7, 2012Publication date: April 4, 2013Applicant: The Corporation of the Trustees of the Order of the Sisters of Mercy in QueenslandInventors: Derek Nigel Hart, David Munster, Peter Vukovic
-
Publication number: 20110097333Abstract: The present invention relates generally to therapeutic and diagnostic agents. More particularly, the present invention provides molecules having structural features characteristic of immunoregulatory signalling (IRS) molecules and which are expressed by cells of haematopoietic lineages such as, in particular, leukocytes. The molecules of the present invention find broad application inter alia as diagnostic markers for cells, targets for cell therapy and as validated drug targets in order to modulate the immune response and to treat, prevent and diagnose a range of diseases conditions including cancer, genetic disease, inflammatory conditions and conditions associated with aberrant haematopoietic cell function or activity. The present invention extends to binding partners of the instant molecules such as, for example, antibodies, ligands, adaptor and other signalling associated molecules, agonists and antagonists and to methods of screening for same.Type: ApplicationFiled: November 24, 2010Publication date: April 28, 2011Applicant: Th Corporation of the Trustees of the Order of the Sisters of Mercy in QueenslandInventors: GEORGINA JANE CLARK, DEREK NIGEL JOHN HART
-
Publication number: 20100303818Abstract: The invention provides isolated human DEC-205, its extracellular domain and functionally equivalent fragments thereof. Also provided are polynucleotides encoding same and vectors which include such polynucleotides. Further provided are methods of recombinantly producing human DEC-205, an extracellular domain thereof or a functionally equivalent fragment, and ligands that bind to human DEC-205 or a fragment thereof. Also provided are constructs for use in prophylaxis or therapy comprising such a ligand, human DEC-205 or an extracellular domain thereof coupled to a toxin or to an antigen capable of inducing a protective immune response in a patient.Type: ApplicationFiled: November 18, 2009Publication date: December 2, 2010Applicant: The Corporation of the Trustees of the Order of the Sisters of Mercy In QueenslandInventor: Derek N. Hart
-
Publication number: 20100303819Abstract: The present invention relates generally to a novel lectin and to derivatives, homologues, analogues, chemical equivalents and mimetics thereof and, more particularly, to a novel type I C-type lectin, herein referred to as “DCL-1”. In particular, the present invention relates to the use of DCL-1 in therapeutic, prophylactic and diagnostic applications.Type: ApplicationFiled: May 10, 2010Publication date: December 2, 2010Applicant: THE CORPORATION OF THE TRUSTEES OF THE ORDER OF THE SISTERS OF MERCY IN QUEENSLANDInventors: DEREK NIGEL JOHN HART, Masato Kato
-
Publication number: 20100111980Abstract: The present invention relates to the field of diagnostics, therapeutics and immunological reagents. More particularly, the present invention provides binding partners of antibodies specific for dendritic cell (DC) antigens. The present invention further provides diagnostic and/or therapeutic agent based on the binding partners or antibodies specific for the binding partners.Type: ApplicationFiled: December 9, 2005Publication date: May 6, 2010Applicant: The Corporation of the Trustees of the Order of the Sisters of Mercy in QueenslandInventors: Derek Nigel Hart, David Munster, Peter Vukovic
-
Publication number: 20090238819Abstract: The present invention relates generally to therapeutic and diagnostic agents. More particularly, the present invention provides molecules having structural features characteristic of immunoregulatory signalling (IRS) molecules and which are expressed by cells of haematopoietic lineages such as, in particular, leukocytes. The molecules of the present invention find broad application inter alia as diagnostic markers for cells, targets for cell therapy and as validated drug targets in order to modulate the immune response and to treat, prevent and diagnose a range of diseases conditions including cancer, genetic disease, inflammatory conditions and conditions associated with aberrant haematopoietic cell function or activity. The present invention extends to binding partners of the instant molecules such as, for example, antibodies, ligands, adaptor and other signalling associated molecules, agonists and antagonists and to methods of screening for same.Type: ApplicationFiled: May 20, 2009Publication date: September 24, 2009Applicant: The Corporation of the Trustees of the Order of the Sisters of Mercy in QueenslandInventors: Georgina Jane Clark, Derek Nigel John Hart
-
Publication number: 20080153159Abstract: The present invention relates generally to therapeutic and diagnostic agents. More particularly, the present invention provides molecules having structural features characteristic of immunoregulatory signalling (IRS) molecules and which are expressed by cells of haematopoietic lineages such as, in particular, leukocytes. The molecules of the present invention find broad application inter alia as diagnostic markers for cells, targets for cell therapy and as validated drug targets in order to modulate the immune response and to treat, prevent and diagnose a range of diseases conditions including cancer, genetic disease, inflammatory conditions and conditions associated with aberrant haematopoietic cell function or activity. The present invention extends to binding partners of the instant molecules such as, for example, antibodies, ligands, adaptor and other signalling associated molecules, agonists and antagonists and to methods of screening for same.Type: ApplicationFiled: January 17, 2008Publication date: June 26, 2008Applicant: The Corporation of the Trustees of the Order of the Sisters of Mercy in QueenslandInventors: Georgina Jane Clark, Derek Nigel John Hart
-
Publication number: 20070184036Abstract: The present invention relates generally to a method for the treatment or prophylaxis of a condition which provokes, or is exacerbated by, an immunological response. The present invention further enables methods of diagnosis of conditions which provoke, or are exacerbated by, an immunological response. The present invention further provides therapeutic and diagnostic agents for conditions which provoke, or are exacerbated by, an immunological response. The present invention further provides compositions of cells defining a sub-population of CD4+ T cells defined by CMRF-35 and CD45RO.Type: ApplicationFiled: October 28, 2004Publication date: August 9, 2007Applicant: The Corporation of the Trustees of the Order of the Sisters of Mercy in QueenslandInventors: Derek Hart, Georgina Clark
-
Publication number: 20050282765Abstract: Enzyme having AHCY-type activity and DNA sequences which encode the enzyme. The enzyme is useful in a screening assay to identify compounds useful as immunosuppression agents.Type: ApplicationFiled: April 21, 2005Publication date: December 22, 2005Applicant: The Corporation of the Trustees of the Order of the Sisters of Mercy in QueenslandInventor: Derek Hart
-
Publication number: 20050186612Abstract: The invention provides isolated human DEC-205, its extracellular domain and functionally equivalent fragments thereof. Also provided are polynucleotides encoding same and vectors which include such polynucleotides. Further provided are methods of recombinantly producing human DEC-205, an extracellular domain thereof or a functionally equivalent fragment, and ligands that bind to human DEC-205 or a fragment thereof. Also provided are constructs for use in prophylaxis or therapy comprising such a ligand, human DEC-205 or an extracellular domain thereof coupled to a toxin or to an antigen capable of inducing a protective immune response in a patient.Type: ApplicationFiled: March 2, 2005Publication date: August 25, 2005Applicant: The Corporation of the Trustees of the Order of the Sisters of Mercy in QueenslandInventor: Derek Hart
-
Publication number: 20040053364Abstract: The invention relates to the receptor CMRF-35-H9 which inter alia bind immunoglobulin M (IgM). The receptor, together with peptides encoding its extracellular domain, have application in methods of immunomodulation, including in the blocking or inhibition of humoral immune responses in transplant patients.Type: ApplicationFiled: January 31, 2003Publication date: March 18, 2004Applicant: The Corporation of the Trustees of the Order of the Sisters of Mercy in QueenslandInventor: Derek N.J. Hart
-
Patent number: 6617428Abstract: Isolated receptor CMRF-35-H9 having an amino acid sequence as set out in SEQ ID NO:1, or a derivative thereof which binds IgM. The receptor, together with peptides encoding its extracellular domain, have application in methods of immunomodulation, including the blocking or inhibition of humoral immune responses in transplant patients.Type: GrantFiled: July 7, 2000Date of Patent: September 9, 2003Assignee: The Corporation of the Trustees of the Order of the Sisters of Mercy in QueenslandInventor: Derek N. J. Hart
-
Publication number: 20030082707Abstract: The invention provides isolated human DEC-205, its extracellular domain and functionally equivalent fragments thereof. Also provided are polynucleotides encoding same and vectors which include such polynucleotides. Further provided are methods of recombinantly producing human DEC-205, an extracellular domain thereof or a functionally equivalent fragment, and ligands that bind to human DEC-205 or a fragment thereof. Also provided are constructs for use in prophylaxis or therapy comprising such a ligand, human DEC-205 or an extracellular domain thereof coupled to a toxin or to an antigen capable of inducing a protective immune response in a patient.Type: ApplicationFiled: May 10, 2002Publication date: May 1, 2003Applicant: The Corporation of the Trustees of the Order of the Sisters of Mercy in QueenslandInventor: Derek N. Hart
-
Patent number: 6479247Abstract: Isolated antibody or preparation of antibodies comprising an antigen-binding domain wherein the antigen is present on activated dendritic cells and wherein the antibody does not interact with CMRF-44 antigen or CD83 antigen.Type: GrantFiled: April 29, 1999Date of Patent: November 12, 2002Assignee: The Corporation of the Trustees of the Order of the Sisters of Mercy in QueenslandInventor: Derek N. J. Hart
-
Publication number: 20020035078Abstract: Enzyme having AHCY-type activity and DNA sequences which encode the enzyme. The enzyme is useful in a screening assay to identify compounds useful as immunosuppression agents.Type: ApplicationFiled: February 14, 2001Publication date: March 21, 2002Applicant: The Corporation of the Trustees of the Order of the Sisters of Mercy in Queensland.Inventor: Derek N.J. Hart